OBJECTIVE: To explore the clinical application value of mineralized collagen (MC) bone scaffolds in repairing various types of skull defects, and to assess the suitability and repair effectiveness of porous MC (pMC) scaffolds, compact MC (cMC) scaffolds, and biphasic MC composite (bMC) scaffolds. METHODS: A retrospective analysis was conducted on the clinical data of 105 patients who underwent skull defect repair with pMC, cMC, or bMC between October 2014 and April 2022. The cohort included 63 males and 42 females, ranging in age from 3 months to 55 years, with a median age of 22.7 years. Causes of defects included craniectomy after traumatic surgery in 37 cases, craniotomy in 58 cases, tumor recurrence or intracranial hemorrhage surgery in 10 cases. Appropriate MC scaffolds were selected based on the patient's skull defect size and age: 58 patients with defects <3 cm² underwent skull repair with pMC (pMC group), 45 patients with defects ≥3 cm² and aged ≥5 years underwent skull repair with cMC (cMC group), and 2 patients with defects ≥3 cm² and aged <5 years underwent skull repair with bMC (bMC group). Postoperative clinical follow-up and imaging examinations were conducted to evaluate bone regeneration, the biocompatibility of the repair materials, and the occurrence of complications. RESULTS: All 105 patients were followed up 3-24 months, with an average of 13 months. No material-related complication occurred in any patient, including skin and subcutaneous tissue infection, excessive ossification, and rejection. CT scans at 6 months postoperatively showed bone growth in all patients, and CT scans at 12 months postoperatively showed complete or near-complete resolution of bone defects in all patients, with 58 cases repaired in the pMC group. The CT values of the defect site and the contralateral normal skull bone in the pMC group at 12 months postoperatively were (1 123.74±93.64) HU and (1 128.14±92.57) HU, respectively, with no significant difference ( t=0.261, P=0.795). CONCLUSION MC exhibits good biocompatibility and osteogenic induction ability in skull defect repair. pMC is suitable for repairing small defects, cMC is suitable for repairing large defects, and bMC is suitable for repairing pediatric skull defects.
Humans ; Tissue Scaffolds ; Male ; Female ; Collagen ; Retrospective Studies ; Adult ; Child ; Adolescent ; Middle Aged ; Child, Preschool ; Skull/surgery* ; Young Adult ; Infant ; Plastic Surgery Procedures/methods* ; Tissue Engineering/methods* ; Craniotomy/methods* ; Bone Regeneration ; Treatment Outcome ; Porosity ; Biocompatible Materials

Recently, avian viral diseases have become one of the main models to study mechanisms of viral infections and pathogenesis. The study of regulatory relationships and mechanisms between viruses and microRNAs has also become the focus. In this review, we briefly summarize the general situations of microRNAs encoded by avian herpesviruses. Also, we analyze the regulatory relationships between tumorigenicity of avian herpesviruses and microRNAs. Additionally, the possible applications for prevention and treatment of viral diseases (such as infectious bursal disease, avian influenza and avian leucosis) using the regulatory mechanisms of microRNAs are also discussed.
Animals ; Avian Leukosis ; Birds ; virology ; Birnaviridae Infections ; Herpesviridae ; genetics ; Influenza in Birds ; MicroRNAs ; genetics

As the efficacies of chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC) have reached a plateau, the molecularly targeted therapy becomes a new method to improve curative effects.The molecular targeted drugs include epidermal growth factor receptor inhibitors, anti-angiogenesis drugs, etc.As one of the representative drugs of EGFR inhibitors, Gefitinib, has a low clinical benefit index.Erlotinib, the first EGFRTK inhibitor, can enhance the survival of patients, and may serve as a potential choice for the first-line treatment of advanced NSCLC.Bevacizumab combined with chemotherapy has shown a favorable clinical effect in the first-line treatment, and it is also the first anti-angiogenesis drug approved by the FDA that can be used in cancer treatment.These drugs, together with clinical and experimental progress in many other targeted drugs, have shown a favorable prospect for targeted drugs in the treatment of advanced non-small cell lung cancer.